Table 4.
Predictive factors for incidence of adverse events on univariate logistic regression analysis
| Univariate analysis | ||||
|---|---|---|---|---|
| OR | 95% CI | P Value | ||
| Age (years) |
< 75 ≥ 75 |
1 0.31 |
- 0.06–1.67 |
- 0.17 |
| Sex |
Male Female |
1 0.76 |
- 0.08–7.37 |
- 0.81 |
| BMI, kg/m2 |
≥ 18.5 < 18.4 |
1 3.33 |
- 0.60–18.70 |
- 0.17 |
| ECOG PS |
2 3–4 |
1 4.60 |
- 0.82–25.90 |
- 0.08 |
| Pathology |
SCC Others |
1 1.21 |
- 0.12–12.60 |
- 0.87 |
| Comorbidity index |
0 ≥ 1 |
1 0.39 |
- 0.08–1.89 |
- 0.24 |
| Clinical T stage* |
cT3 cT4 |
1 7.78 |
- 0.87–69.50 |
- 0.07 |
| Clinical N stage* |
N0 N1-3 |
1 0.92 |
- 0.38–2.25 |
- 0.86 |
| Clinical M stage* |
M0 M1 |
1 1.00 |
- 0.22–4.59 |
- 1.00 |
| Dysphagia score |
2 3–4 |
1 6.30 |
- 0.71–56.30 |
- 0.10 |
| Primary tumor length, cm |
< 7.0 ≥ 7.0 |
1 2.43 |
- 0.43–13.60 |
- 0.31 |
| Number of metastatic sites |
0–1 ≥ 2 |
1 1.07 |
- 0.18–6.28 |
- 0.94 |
| Primary tumor location |
Thoracic GEJ |
1 3.89 |
- 0.53–28.40 |
- 0.18 |
| GPS |
0 1–2 |
1 13.5 |
- 1.49–121.00 |
- 0.02 |
*Cancer staging followed the Union for International Cancer Control 8th edition guidelines. OR: odds ratio; CI: confidence interval; BMI: body mass index; ECOG PS: Eastern Cooperative Oncology Group performance status; SCC: squamous cell carcinoma; GEJ: gastro-esophageal junction; GPS: Glasgow Prognostic Score